• EMA's CHMP recommended expanding approval of Ionis Pharmaceuticals' TRYNGOLZA to adults with severe hypertriglyceridemia with fasting triglycerides ≥880 mg/dL.
• A final European Commission decision is expected in the fourth quarter of 2026, ahead of the previously anticipated timeline.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ionis Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261015217326) on October 16, 2026, and is solely responsible for the information contained therein.